<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01886794</url>
  </required_header>
  <id_info>
    <org_study_id>13-114</org_study_id>
    <nct_id>NCT01886794</nct_id>
  </id_info>
  <brief_title>Hormonal Status on Blood Flow and Tissue in Pelvic Organ Prolapse</brief_title>
  <official_title>Role of Hormonal Status on Vascularization and Vaginal Tissue in Women With Pelvic Organ Prolapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our primary aim in the current study is to determine important tissue differences, including&#xD;
      muscle and connective tissue changes, between postmenopausal women and reproductive age women&#xD;
      with pelvic floor dysfunction to help develop targeted and noninvasive treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our primary aim in the current study is to determine important tissue differences, including&#xD;
      muscle and connective tissue changes, between postmenopausal women and reproductive age women&#xD;
      with pelvic floor dysfunction to help develop targeted and noninvasive treatments. We will&#xD;
      perform in vivo evaluations with colposcopy and OCT to determine epithelial thickness and&#xD;
      overall mucosal health prior to surgery. At the time of surgery, we will obtain tissue for&#xD;
      histologic and imaging analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vaginal epithelial thickness</measure>
    <time_frame>1-month perioperative study</time_frame>
    <description>Measure of vaginal epithelial thickness obtained by optical coherence tomography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Histologic assessment of excised tissue</measure>
    <time_frame>1-month perioperative study</time_frame>
    <description>Evaluation of histology from surgery for collagen and elastin</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Pelvic Floor Disorders</condition>
  <arm_group>
    <arm_group_label>Postmenopausal, topical vaginal cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Postmenopausal participants randomized to topical vaginal cream containing estrogen or placebo for about one month's use prior to scheduled surgery. These will include those women randomized to estrogen cream.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-menopausal, no topical vaginal cream</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Pre-menopausal, no topical vaginal cream. These women will be examined at different stages in their menstrual cycle in order to compare characteristics of the cycle at high and lower estrogen timepoints.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Postmenopausal, topical placebo cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Postmenopausal participants randomized to topical vaginal cream containing estrogen or placebo for about one month's use prior to scheduled surgery. These will include those women randomized to placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Postmenopausal, topical vaginal estrogen cream</intervention_name>
    <description>Topical vaginal estrogen cream is commonly but not universally used to improve the health of vaginal tissue prior to surgery. This study will provide data regarding estrogen effects for post-menopausal women undergoing pelvic organ prolapse.</description>
    <arm_group_label>Postmenopausal, topical vaginal cream</arm_group_label>
    <other_name>Estrace vaginal cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator: Postmenopausal, topical placebo cream</intervention_name>
    <description>Postmenopausal participants randomized to topical vaginal placebo for about one month's use prior to scheduled surgery.</description>
    <arm_group_label>Postmenopausal, topical placebo cream</arm_group_label>
    <other_name>Placebo vaginal cream</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  21 to 70 years of age&#xD;
&#xD;
          -  Stage II or greater pelvic organ prolapse (POP)&#xD;
&#xD;
          -  Individuals electing surgery to treat their POP&#xD;
&#xD;
          -  Willing and able to comply with study procedures&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication for estrogen cream&#xD;
&#xD;
          -  Any medical condition that in the opinion of the investigator would place the subject&#xD;
             at increased risk for participation&#xD;
&#xD;
          -  History of connective tissue disease&#xD;
&#xD;
          -  Previous hysterectomy or pelvic organ prolapse surgery&#xD;
&#xD;
          -  Known allergic reaction to any agent required by the protocol&#xD;
&#xD;
          -  Use of hormone therapy in postmenopausal women in the last 90 days&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  History of prior noncompliance or the presence or history of psychiatric condition&#xD;
             that would in the opinion of the investigator make it difficult for the subject to&#xD;
             comply with study procedures or follow instructions&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen Vincent, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UTMB Galveston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UTMB Galveston</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.utmbhealth.com/PelvicHealth</url>
    <description>Link to the clinic where recruitment will be performed</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 14, 2013</study_first_submitted>
  <study_first_submitted_qc>June 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2013</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pelvic floor dysfunction</keyword>
  <keyword>pelvic organ prolapse</keyword>
  <keyword>vaginal estrogen effects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pelvic Floor Disorders</mesh_term>
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

